Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry

Eric Lawrence Matteson, A. R. Hickey, L. Maguire, H. H. Tilson, M. B. Urowitz, M. Fletcher, L. Houle, P. Furci

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

The Rheumatoid Arthritis Azathioprine Registry (RAAR) was established in 1982 to examine the safety of azathioprine (AZA) and other disease modifying agents (DMARD) in the treatment of RA. In yearly followup over the past 7 years, 20 malignant conditions have been reported in 530 DMARD treated adult patients with RA. Incidence density ratios (IDR) and standardized morbidity ratios (SMR) were calculated to assess cancer risk. For all cancers the SMR was 1.52 (95% CI 0.90-2.60). For men the SMR was 1.71 (95% CI 0.84-3.52); for women the SMR was 1.52 (95% CI 0.89-2.60). Adjusted for age, the IDR was highest in the 70-79-year-old study population (3.41). The age and sex adjusted SMR for lymphoproliferative disorders and myeloma was 8.05 (95% CI 3.30-20.81). The SMR for lung cancer (n = 6) was also increased (3.37; 95% CI 1.58-7.34). Compared with the general population, patients with RA requiring DMARD therapy may be at increased risk of malignancy, particularly lymphoproliferative disorders. The RAAR is an important prospective technique which will ultimately permit assessment of neoplasia risk by type and duration of DMARD therapy.

Original languageEnglish (US)
Pages (from-to)809-814
Number of pages6
JournalJournal of Rheumatology
Volume18
Issue number6
StatePublished - 1991

Fingerprint

Antirheumatic Agents
Registries
Rheumatoid Arthritis
Morbidity
Azathioprine
Neoplasms
Lymphoproliferative Disorders
Incidence
Population
Lung Neoplasms
Therapeutics
Safety

Keywords

  • cancer
  • DMARD
  • pharmacoepidemiology
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Matteson, E. L., Hickey, A. R., Maguire, L., Tilson, H. H., Urowitz, M. B., Fletcher, M., ... Furci, P. (1991). Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Journal of Rheumatology, 18(6), 809-814.

Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. / Matteson, Eric Lawrence; Hickey, A. R.; Maguire, L.; Tilson, H. H.; Urowitz, M. B.; Fletcher, M.; Houle, L.; Furci, P.

In: Journal of Rheumatology, Vol. 18, No. 6, 1991, p. 809-814.

Research output: Contribution to journalArticle

Matteson, EL, Hickey, AR, Maguire, L, Tilson, HH, Urowitz, MB, Fletcher, M, Houle, L & Furci, P 1991, 'Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry', Journal of Rheumatology, vol. 18, no. 6, pp. 809-814.
Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB, Fletcher M et al. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Journal of Rheumatology. 1991;18(6):809-814.
Matteson, Eric Lawrence ; Hickey, A. R. ; Maguire, L. ; Tilson, H. H. ; Urowitz, M. B. ; Fletcher, M. ; Houle, L. ; Furci, P. / Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. In: Journal of Rheumatology. 1991 ; Vol. 18, No. 6. pp. 809-814.
@article{6c311652c726437193e76cc3aa3f8eb8,
title = "Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry",
abstract = "The Rheumatoid Arthritis Azathioprine Registry (RAAR) was established in 1982 to examine the safety of azathioprine (AZA) and other disease modifying agents (DMARD) in the treatment of RA. In yearly followup over the past 7 years, 20 malignant conditions have been reported in 530 DMARD treated adult patients with RA. Incidence density ratios (IDR) and standardized morbidity ratios (SMR) were calculated to assess cancer risk. For all cancers the SMR was 1.52 (95{\%} CI 0.90-2.60). For men the SMR was 1.71 (95{\%} CI 0.84-3.52); for women the SMR was 1.52 (95{\%} CI 0.89-2.60). Adjusted for age, the IDR was highest in the 70-79-year-old study population (3.41). The age and sex adjusted SMR for lymphoproliferative disorders and myeloma was 8.05 (95{\%} CI 3.30-20.81). The SMR for lung cancer (n = 6) was also increased (3.37; 95{\%} CI 1.58-7.34). Compared with the general population, patients with RA requiring DMARD therapy may be at increased risk of malignancy, particularly lymphoproliferative disorders. The RAAR is an important prospective technique which will ultimately permit assessment of neoplasia risk by type and duration of DMARD therapy.",
keywords = "cancer, DMARD, pharmacoepidemiology, rheumatoid arthritis",
author = "Matteson, {Eric Lawrence} and Hickey, {A. R.} and L. Maguire and Tilson, {H. H.} and Urowitz, {M. B.} and M. Fletcher and L. Houle and P. Furci",
year = "1991",
language = "English (US)",
volume = "18",
pages = "809--814",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "6",

}

TY - JOUR

T1 - Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry

AU - Matteson, Eric Lawrence

AU - Hickey, A. R.

AU - Maguire, L.

AU - Tilson, H. H.

AU - Urowitz, M. B.

AU - Fletcher, M.

AU - Houle, L.

AU - Furci, P.

PY - 1991

Y1 - 1991

N2 - The Rheumatoid Arthritis Azathioprine Registry (RAAR) was established in 1982 to examine the safety of azathioprine (AZA) and other disease modifying agents (DMARD) in the treatment of RA. In yearly followup over the past 7 years, 20 malignant conditions have been reported in 530 DMARD treated adult patients with RA. Incidence density ratios (IDR) and standardized morbidity ratios (SMR) were calculated to assess cancer risk. For all cancers the SMR was 1.52 (95% CI 0.90-2.60). For men the SMR was 1.71 (95% CI 0.84-3.52); for women the SMR was 1.52 (95% CI 0.89-2.60). Adjusted for age, the IDR was highest in the 70-79-year-old study population (3.41). The age and sex adjusted SMR for lymphoproliferative disorders and myeloma was 8.05 (95% CI 3.30-20.81). The SMR for lung cancer (n = 6) was also increased (3.37; 95% CI 1.58-7.34). Compared with the general population, patients with RA requiring DMARD therapy may be at increased risk of malignancy, particularly lymphoproliferative disorders. The RAAR is an important prospective technique which will ultimately permit assessment of neoplasia risk by type and duration of DMARD therapy.

AB - The Rheumatoid Arthritis Azathioprine Registry (RAAR) was established in 1982 to examine the safety of azathioprine (AZA) and other disease modifying agents (DMARD) in the treatment of RA. In yearly followup over the past 7 years, 20 malignant conditions have been reported in 530 DMARD treated adult patients with RA. Incidence density ratios (IDR) and standardized morbidity ratios (SMR) were calculated to assess cancer risk. For all cancers the SMR was 1.52 (95% CI 0.90-2.60). For men the SMR was 1.71 (95% CI 0.84-3.52); for women the SMR was 1.52 (95% CI 0.89-2.60). Adjusted for age, the IDR was highest in the 70-79-year-old study population (3.41). The age and sex adjusted SMR for lymphoproliferative disorders and myeloma was 8.05 (95% CI 3.30-20.81). The SMR for lung cancer (n = 6) was also increased (3.37; 95% CI 1.58-7.34). Compared with the general population, patients with RA requiring DMARD therapy may be at increased risk of malignancy, particularly lymphoproliferative disorders. The RAAR is an important prospective technique which will ultimately permit assessment of neoplasia risk by type and duration of DMARD therapy.

KW - cancer

KW - DMARD

KW - pharmacoepidemiology

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0025787402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025787402&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 809

EP - 814

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 6

ER -